Tag: DiscGenics
DiscGenics receives FDA RMAT designation for IDCT for degenerative disc disease
DiscGenics has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy...
DiscGenics reveals positive interim data of cell therapy for degenerative disc...
DiscGenics has announced positive interim data from its ongoing phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative...
Japanese study of disc degeneration cell therapy passes safety review
IDCT (DiscGenics) has passed the initial safety review of its double blinded clinical study evaluating the allogenic, injectable disc cell therapy in Japanese patients...
IDCT clinical study passes final safety review
DiscGenics has announced that it has received the go-ahead from an independent data safety monitoring committee (DSMC) to enrol the final 24 patients in...
DiscGenics receives FDA fast track designation for disc degeneration cell therapy
DiscGenics has announced that the US Food and Drug Administration (FDA) has granted fast track designation for its investigational cell therapy, IDCT, currently being...
First patients treated in Japanese clinical trial of cell therapy for...
DiscGenics today announced the first patients have been treated in its Japanese safety study, a clinical trial of IDCT for mild to moderate degenerative...
Cell therapy IDCT passes initial safety review of first-in-human clinical trial...
It has been announced that IDCT (DiscGenics) has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc...
Clinical evaluation of non-surgical degenerative disc disease treatment to begin in...
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved a Clinical Trial Notification (CTN) application for IDCT (DiscGenics), an allogenic injectable disc cell...
First patient treated in US clinical trial of IDCT for degenerative...
DiscGenics, a clinical stage regenerative medicine company, has announced the first patient has been treated in its phase I/II US clinical trial of IDCT...
DiscGenics’ IDCT Investigational New Drug application accepted by US FDA
DiscGenics has been notified by the US Food and Drug Administration (FDA) that an Investigational New Drug (IND) application for a clinical study of...
DiscGenics granted 9 new patents for DiscoGenic Cell technology
DiscGenics has been granted 9 new patents, expanding its intellectual property portfolio within both the US and globally to 24 issued patents. The new...